Regencell Bioscience Limited (RGC) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Regencell Bioscience Lim...

    NASDAQ: RGC · Real-Time Price · USD
    15.31
    0.17 (1.12%)
    At close: Sep 26, 2025, 1:11 PM

    Regencell Bioscience Income Statement

    Financials in USD. Fiscal year is July - June.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Jun 30, 2024 Jun 30, 2023 Jun 30, 2022 Jun 30, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 745.59K 769.69K 604.4K 26.46K
    Gross Profit
    		 -745.59K -769.69K -604.4K -26.46K
    Operating Income
    		 -4.74M -6.27M -7.62M -1.38M
    Interest Income
    		 n/a n/a n/a n/a
    Pretax Income
    		 -4.36M -6.06M -7.59M -1.35M
    Net Income
    		 -4.3M -5.87M -7.42M -1.35M
    Selling & General & Admin
    		 2.92M 4.69M 5.11M 943.04K
    Research & Development
    		 1.07M 1.58M 2.51M 438.32K
    Other Expenses
    		 n/a 211.34K 23.21K 34.62K
    Operating Expenses
    		 3.99M 6.27M 7.62M 1.38M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 125.43K 262.66K 25.27K 1.58K
    Cost & Expenses
    		 4.74M 6.27M 7.62M 1.38M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 494.49M 494.49M 494.49M 480.4M
    Shares Outstanding (Diluted)
    		 494.49M 494.49M 494.49M 480.4M
    EPS (Basic)
    		 -0.01 -0.01 -0.01 -0.00
    EPS (Diluted)
    		 -0.01 -0.01 -0.01 -0.00
    EBITDA
    		 -3.62M -5.29M -6.99M -1.35M
    EBIT
    		 -4.36M -6.27M -7.62M -1.38M
    Depreciation & Amortization
    		 745.59K 769.69K 604.4K 26.46K

    Add to Watchlist